HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) – Equities researchers at HC Wainwright dropped their FY2025 earnings estimates for shares of GENFIT in a note issued to investors on Wednesday, September 24th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($0.17) per share for the year, down from their prior estimate of $0.01. HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for GENFIT’s current full-year earnings is $0.95 per share. HC Wainwright also issued estimates for GENFIT’s FY2026 earnings at ($0.63) EPS, FY2027 earnings at $0.15 EPS, FY2028 earnings at ($0.51) EPS and FY2029 earnings at ($0.28) EPS.

GENFIT Stock Performance

Shares of NASDAQ GNFT opened at $3.53 on Friday. The business’s fifty day moving average price is $4.00 and its 200-day moving average price is $3.90. GENFIT has a one year low of $2.55 and a one year high of $6.42. The company has a quick ratio of 1.23, a current ratio of 3.74 and a debt-to-equity ratio of 0.09.

Hedge Funds Weigh In On GENFIT

A hedge fund recently bought a new stake in GENFIT stock. Millennium Management LLC acquired a new position in shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned approximately 0.33% of GENFIT at the end of the most recent quarter. 2.24% of the stock is currently owned by hedge funds and other institutional investors.

About GENFIT

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.